Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19

dc.date.accessioned	2023-03-06T07:32:21Z
dc.date.available	2023-03-06T07:32:21Z
dc.date.issued	2021
dc.identifier.citation	J Clin Pharm Ther. 2021 Apr;46(2):454-459. doi: 10.1111/jcpt.13305. Epub 2020 Oct 31.
dc.identifier.uri	https://hdl.handle.net/20.500.12619/100285
dc.relation.isversionof	10.1111/jcpt.13305
dc.relation.isversionof	10.1111/jcpt.13305
dc.title	Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19
dc.relation.journal	J Clin Pharm Ther
dc.identifier.doi	10.1111/jcpt.13305
dc.contributor.author	Kocayiğit H
dc.contributor.author	Kocayiğit H
dc.contributor.author	Özmen Süner K
dc.contributor.author	Tomak Y
dc.contributor.author	Demir G
dc.contributor.author	Yaylacı S
dc.contributor.author	Dheir H
dc.contributor.author	Güçlü E